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Abstract
Human luteinizing hormone (hLH) and chorionic gonadotropin (hCG) act on the same receptor (LHCGR) but it is not known
whether they elicit the same cellular and molecular response. This study compares for the first time the activation of cell-
signalling pathways and gene expression in response to hLH and hCG. Using recombinant hLH and recombinant hCG we
evaluated the kinetics of cAMP production in COS-7 and hGL5 cells permanently expressing LHCGR (COS-7/LHCGR, hGL5/
LHCGR), as well as cAMP, ERK1/2, AKT activation and progesterone production in primary human granulosa cells (hGLC). The
expression of selected target genes was measured in the presence or absence of ERK- or AKT-pathways inhibitors. In COS-7/
LHCGR cells, hCG is 5-fold more potent than hLH (cAMP ED50: 107.1614.3 pM and 530.0651.2 pM, respectively). hLH
maximal effect was significantly faster (10 minutes by hLH; 1 hour by hCG). In hGLC continuous exposure to equipotent
doses of gonadotropins up to 36 hours revealed that intracellular cAMP production is oscillating and significantly higher by
hCG versus hLH. Conversely, phospho-ERK1/2 and -AKT activation was more potent and sustained by hLH versus hCG. ERK1/
2 and AKT inhibition removed the inhibitory effect on NRG1 (neuregulin) expression by hLH but not by hCG; ERK1/2
inhibition significantly increased hLH- but not hCG-stimulated CYP19A1 (aromatase) expression. We conclude that: i) hCG is
more potent on cAMP production, while hLH is more potent on ERK and AKT activation; ii) hGLC respond to equipotent,
constant hLH or hCG stimulation with a fluctuating cAMP production and progressive progesterone secretion; and iii) the
expression of hLH and hCG target genes partly involves the activation of different pathways depending on the ligand.
Therefore, the LHCGR is able to differentiate the activity of hLH and hCG.
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Introduction
Luteinizing hormone (LH) and chorionic gonadotropin (CG)
are heterodimeric glycoprotein hormones acting on the same
receptor, the luteinizing hormone-chorionic gonadotropin recep-
tor (LHCGR) [1], which is found as dimer/oligomer at the cell
membrane [2]. LH is the physiological hormone in non-pregnant
women, produced by the pituitary in a pulsatile fashion. LH binds
to LHCGR on the granulosa cells surface, resulting in progester-
one production, ovulation, luteinization and corpus luteum
formation [3]. Moreover, LH stimulates androstenedione and
testosterone production in theca cells. In the human ovary,
androstenedione is aromatized to estrone by granulosa cells and
finally converted to estradiol by 17-b-hydroxysteroid dehydroge-
nase type I, representing the system known as the two-cell-two-
gonadotropin regulation of estrogen synthesis [3]. After the
ovulation, LH supports the transient life span of the corpus
luteum acting on the luteinized granulosa cells [3]. Conversely,
CG is a hormone produced mainly by placental trophoblast cells
during pregnancy in an increasing, non-pulsatile fashion [4]. Apart
from equine CG (eCG), which mediates a predominant FSH-like
activity [5], CG with exclusive, unique LH-like activity exists only
in primates and its b-subunit gene is present in increasing copy
number, according to the increasing structural complexity of
placental implantation in the primate species [6].
Human LH (hLH) and CG (hCG) differ in their half-life (60–
120 minutes for hLH, several hours for hCG [7–13] and in some
structural features, such as the presence of a carboxyl terminal
peptide (CTP) and the type and amount of glycosylation. Due to
this heterogeneity and derivation from extractive preparations,
gonadotropins have been difficult to quantify accurately in the
past, and most in vitro experiments have been conducted using
urinary hCG calibrated by in vivo bioassay against standard
preparations expressed in activity units [14]. With the advent of
recombinant gonadotropins, highly homogeneous and consistent
r-hLH and r-hCG can be accurately quantified in molar terms
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[15] and used to compare their effects in vitro at exactly equimolar
concentrations.
Being structurally different, it should be expected that hLH and
hCG display different hormone-receptor interaction features and,
consequently, might be not equivalent at molecular and cellular
level. There are some hints that hLH and hCG may not have the
same activity. Some residues of the LHCGR extracellular domain
are indeed able to differentiate binding of hLH and hCG [16] and
the human LHCGR can react differently to hLH and hCG when
exon 10 is lacking (LHCGR-10) [17]. LHCGR-10 can bind either
gonadotropin with similar affinity but cAMP production is
drastically impaired upon hLH but not hCG stimulation
[17,18], suggesting that exon 10 of the LHCGR can distinguish
between hLH and hCG. Whether this translates physiologically
into preferential activation of different signal transduction
pathways and, eventually, different cell responses, is not known.
Some LHCGR-dependent effects are mediated by the activa-
tion of the cyclic AMP-protein kinase A (cAMP/PKA) pathway,
which stimulates progesterone production and has been associated
to morphological changes [19] and apoptosis [20,21] in granulosa
cells. However, additional signalling pathways (e.g. AKT- and
ERK1/2-pathways) are involved [1] in LHCGR-dependent events
such as proliferation, differentiation and survival [22], for example
via expression of EGF-like growth factors [23]. Lastly, aromatase
expression and steroidogenic function via LHCGR activation are
likely to involve cAMP/PKA, ERK1/2 and AKT pathways, all
playing a crucial role in the final stages of maturation of human
oocytes and follicles [24,25].
While equivalence of hLH and hCG in activating the
downstream signaling of LHCGR is presumed, this issue has
never been investigated thoroughly so far. In this work, after
confirming that extractive and recombinant gonadotropins are
equivalent in essence as far as their effects in vitro are concerned,
we evaluated the effects of hLH and hCG on the cell response by
systematically assessing the activation of cAMP/PKA-, ERK1/2-
and AKT-pathways in three validated in vitro models consisting of
a COS-7 cell line permanently transfected with human LHCGR
(COS-7/LHCGR) [18], the immortalized human granulosa cell
line hGL5 [26] permanently transfected with the human LHCGR
(hGL5/LHCGR) and human primary granulosa cells (hGLC)
[27]. The COS-7/LHCGR cell system is a standardized model,
constitutively expressing a fix number of LHCGR under the
transcriptional regulation of the cytomegalovirus promoter [18].
Conversely, primary hGLC obtained from women undergoing
assisted reproduction procedures naturally express the LHCGR,
which is presumably subjected to ‘‘physiological’’ control of
LHCGR gene transcription and different modulation of the
desensitization mechanisms [28]. Finally, the hGL5 cell line
derives from human granulosa cells immortalized by transforma-
tion with the E6 and E7 regions of human papillomavirus. Despite
their steroidogenic activity, hGL5 cells do not naturally express
gonadotropin receptors [26] and were permanently transfected
with the human LHCGR for this study. These cell model were
used to assess the kinetics of cAMP and progesterone production
and to investigate some intracellular events following acute and
chronic exposure to equipotent hLH and hCG doses. Remarkable
differences in LH and hCG action were demonstrated.
Methods
A detailed description of the methods is available as Methods
S1.
Recombinant and extractive gonadotropins
Human, highly purified recombinant LH (r-hLH; Luveris) and
CG (r-hCG; Ovitrelle) were kindly provided by Merck-Serono
S.p.A. (Rome, Italy). LH extracted from human pituitary (ex-hLH)
and CG extracted from human pregnancy urine (ex-hCG) were
purchased by Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO).
Cell lines
A COS-7 cell line permanently transfected with LHCGR wild
type (COS-7/LHCGR) was kindly provided by Prof. Gromoll
(Centre for Reproductive Medicine and Andrology, University of
Mu¨nster, Germany). The immortalized human granulosa cell line
hGL5 [26] was permanently transfected by electroporation with
LHCGR wild type. For stable transfection we used the pTracer
vector (Invitrogen, Leek, The Netherlands), containing the
cytomegalovirus promoter in front of the multiple cloning site
and the green fluorescent protein reporter gene [18]. COS-7/
LHCGR cells were cultured in DMEM supplemented with 10%
FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin. This cell line, overexpressing the human LHCGR,
was extensively validated previously [18]. hGL5/LHCGR cells
were cultured in DMEM/F12 supplemented with 10% FBS, 2%
Ultroser G, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin. All cell lines were maintained in an incubator at
37uC and with 5% CO2.
Granulosa-lutein cell isolation and culture
Human primary granulosa-lutein cells (hGLC) were isolated
from ovarian follicles of women undergoing oocyte retrieval for
assisted reproduction technologies (ART). The cells from 3–4
different patients were pooled and collected using a 50% Percoll
gradient (GE Healthcare, Little Chalfont, UK) following a
procedure previously described [27], then cultured in a CO2 cell
incubator. Before each experiment, granulosa cells were main-
tained in culture until day 6, to allow the recovery of the response
to gonadotropins (Fig. S1).
Patients selection
Women undergoing ovarian stimulation for infertility due to
tubal or male factor were included. Study approval was obtained
from the local ethics committee and informed, written consent was
obtained from each patient. (Ethics committee approval - dossier
number: Pratica 161/11, date: 21 september 2011, Prot. n. 3186/
C.E. Comitato Etico Provinciale di Modena). The patients had to
match the following criteria: absence of endocrine abnormalities;
absence of severe viral or bacterial infections; age between 25–45
years.
cAMP stimulation protocols
For cAMP stimulation a validated protocol was followed [27].
The COS-7/LHCGR, hGL5/LHCGR and granulosa cells were
seeded in triplicate in 24-well plates for cAMP dose-response
experiments and serum starved 12 hours before the experiments.
Cells were stimulated using increasing doses of r-hLH, r-hCG, ex-
hLH or ex-hCG as appropriate (ranging between 0.1 pM-1 mM)
in the presence of 500 mM IBMX (Sigma-Aldrich). Total cAMP
was measured after 3 hours incubation and the cAMP ED50 values
for hLH and hCG were calculated. A total of 4 independent
experiments were performed.
To evaluate the kinetics of response to continuous exposure to
gonadotropins, time-course experiments were performed. The
COS-7/LHCGR and hGLC were stimulated using the cAMP
equipotent ED50 doses of r-hLH or r-hCG, for different times
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ranging between 5 minutes and 36 hours in the presence of
IBMX. The intracellular cAMP was measured after each
incubation. Cell viability was also evaluated [29]. A total of 3
independent experiments were performed.
The quantitative detection of cAMP was performed in triplicate
by a competitive ELISA kit and the data were entered into a curve
fitting software which extrapolates the cAMP concentration
against a standard curve. The data were represented using a log
regression analysis.
Immunofluorescence analysis of human granulosa cells
Immunofluorescence analysis was performed to evaluate the
kinetics of receptor internalization resulting from continuous in
vitro stimulation of hGLC by gonadotropins. Serum-starved hGLC
were stimulated for different times with the ED50 dose of hLH or
hCG. After stimulation, the cells were fixed and sequentially
incubated with anti-LHCGR [30] and anti-ERK1/2 antibody to
be observed in confocal microscopy. Negative and positive
controls for the antibodies and non-permeabilized cells were also
included.
Phospho-ERK1/2 and phospho-AKT stimulation and
Western blot analysis
To evaluate the doses of r-hLH, r-hCG, ex-hLH or ex-hCG
resulting in the maximum level of stimulation of ERK1/2- and
AKT-pathway (EDMAX), dose-response experiments were per-
formed. 12 hours serum-starved hGLC were stimulated for
15 minutes [31,32] with increasing doses of r-hLH or r-hCG
(ranging between 0.1 pM-1 mM), including negative controls. To
compare the response to recombinant versus extractive gonadotro-
pins also hGL5/LHCGR cells were used. In time-course
experiments the cells were then stimulated over 1 hour with
100 pM r-hLH or r-hCG (EDMAX), previously obtained in dose-
response experiments. Negative controls were included in each
step of the time-course experiment. The cells were immediately
lysed for protein extraction in 4uC-cold RIPA buffer added with
protease and phosphatase inhibitors. A total of 4 independent
experiments were performed by using each time a different pool of
granulosa cells obtained from 3–4 different patients.
Phospho-ERK1/2 and phospho-AKT activation were evaluat-
ed by Western blot analysis after 12% SDS-PAGE. Equal protein
loading was confirmed against total ERK1/2 after stripping the
membranes. The signals were revealed by chemiluminescence,
then acquired and semi-quantitatively evaluated by an image
analysis system.
Stimulation for gene expression analysis
Serum-starved hGLC were stimulated for 12 hours with r-hLH
or r-hCG EDMAX. One-hour pre-incubated samples with ERK1/
2- or AKT-pathway inhibitors were also included. After stimula-
tion, total RNA was extracted and an equal amount in cDNA
synthesis reactions was used.
Real-time PCR analysis
Real-time PCR was performed in triplicates with the primers
shown in Table 1. The ribosomal protein S7 (RPS7) gene was used as
normalizer. The thermal cycling settings for all genes were the
following: 45 cycles of 30 s of melting at 95uC followed by 10 s of
annealing and extension at 60uC. Normalized gene expression was
evaluated using the 22DCt method [33] and expressed as fold
increase over its unstimulated sample (basal level). A total of four
experiments were performed.
Statistical analysis
Each value obtained from hLH and hCG-stimulated cells was
normalized for the corresponding control value. In time-course
experiments for ERK1/2 and AKT, the semi-quantitative
evaluations were graphically expressed in relative units. Data are
expressed as means 6 SEM. Mann Whitney’s U-test, unpaired T-
test or two-way analysis of variance were performed where
appropriate. In time-course experiments, each data-set was
verified with D’Agostino and Pearson normality test (alpha = 0.05).
Values were considered statistically significant for P,0.05.
Results
Short-term kinetics of cAMP production
To evaluate whether r-hLH and r-hCG stimulation of the
human LHCGR results in the same kinetics of cAMP production
we performed dose-response and time course-experiments using
the COS-7/LHCGR cell line. This model allows testing the early
effects of the two gonadotropins in ‘‘steady’’ receptor conditions,
since no regulation of LHCGR gene transcription occurs in these
stably transfected cells constitutively expressing the LHCGR
under the control of the cytomegalovirus promoter. Dose-response
studies were performed by measuring total cAMP after 3 hours of
stimulation with increasing doses of hCG or hLH in the presence
of IBMX (500 mM). A significant difference in the kinetics of total
cAMP production was found, with dose-response curves shifted
significantly to the left in the case of hCG. As shown in Fig. 1, the
ED50 of r-hCG (107.1614. 3 pM) resulted approximately 5 times
lower than the ED50 of r-hLH (530.0651.2 pM) (n= 4, p,0.05,
Fig. 1A). Since recombinant gonadotropins could differ from
pituitary hLH and urinary hCG in the extent and type of
glycosylation this could affect cAMP production, making the
results obtained with ‘‘artificial’’ gonadotropins potentially differ-
ent from those with ‘‘natural’’ gonadotropins. To assess this, a
comparison between both type of gonadotropins was performed in
different cell models (Fig. S2). The results obtained were similar,
indicating that recombinant and extractive gonadotropins result in
comparable effects on activation of signaling pathways, as
otherwise well known from clinical practice.
The ED50 doses of r-hLH and r-hCG were then used in time-
course experiments, based on the measurement of intracellular
cAMP in COS-7/LHCGR cells stimulated for up to 180 minutes
by r-hLH (500 pM) or r-hCG (100 pM), in the presence of
500 mM IBMX (500 mM). Using equipotent doses, accumulation
of intracellular cAMP by r-hLH resulted significantly faster, with
maximal activation achieved in 10 minutes, while, by r-hCG, the
same levels of maximal stimulation were attained only after
60 minutes of stimulation (Fig. 1B). Maximal intracellular cAMP
accumulation was approximately 20–30 times higher than basal
levels in untreated cells and was equally reached in both r-hLH-
and r-hCG-stimulated cells, confirming that the ED50 doses were
indeed equipotent in acute activation. After the first 60 min of
continuous exposure to r-hLH or r-hCG intracellular cAMP
concentrations remained elevated (Fig. 1B). Therefore, equimolar
concentrations r-hLH and r-hCG possess significantly different in
vitro potency (in terms of cAMP) and equipotent concentrations of
r-hLH and r-hCG stimulate intracellular cAMP accumulation
with significantly different kinetics.
When repeated in hGLC cells the cAMP dose-response and
time course experiments confirmed the same difference between r-
hLH and r-hCG (Fig. S3).
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Long-term kinetics of cAMP and progesterone
production in hGLC continuously exposed to hLH or hCG
hGLC obtained at oocyte pickup in ART programs are a well-
known, widely used model for the study of cellular response to
gonadotropins [27] and constitute a more physiological model
than COS-7/LHCGR cells, since they naturally express the
LHCGR and display physiological control of the receptor gene
transcription and downregulation in vitro [31]. In preliminary
experiments we determined that hGLC do not respond signifi-
cantly, in terms of cAMP production, to r-hLH or r-hCG for up to
four days in culture but respond optimally on day 6 (Fig. S1), as
previously described for FSH as well [27]. To compare the kinetics
of intracellular cAMP beyond the first 60 min hGLC were
stimulated on culture day 6 with ED50 doses of r-hLH or r-hCG
for up to six hours. Intracellular cAMP levels decreased after the
first three hours but were not extinguished by 360 min (Fig. S4).
We therefore performed long-term stimulation experiments in
which day 6 hGLC were exposed to constant ED50 doses of r-hLH
(500 pM) or r-hCG (100 pM) for up to 36 hours. As shown in
Fig. 2, continuous exposure to r-hLH or r-hCG resulted in
repetitive, cyclic rises and falls of intracellular cAMP with peaks
approximately every 4–5 hours, while cAMP remained substan-
tially constant in the unstimulated control cells. Moreover, cAMP
concentrations during the peaks were often significantly higher
upon r-hCG stimulation, in spite of the five-fold lower molar
concentrations used, for the first 36 hours (Fig. 3). Intracellular
cAMP response tended to extinguish after 30 hours for both r-
hLH and r-hCG stimulations. The fluctuations in cellular cAMP
response to constant r-hLH or r-hCG doses resulted in progres-
sive, linear accumulation of progesterone in the supernatant,
which increased 45-times, from about 200 ng/ml to about
9000 ng/ml, by 36 hours (Fig. 2) for both r-hLH and r-hCG
stimulations in spite of overall lower cAMP level stimulated by r-
hLH. r-hLH and r-hCG concentrations in the supernatant
(measured by an immunometric assay) and cell viability (measured
by MTT assay) remained constant during the entire stimulation
period (data not shown). The fluctuations in intracellular cAMP
were accompanied a constant increase of extracellular cAMP
measured in the culture medium (Fig. 2D), suggesting the existence
of a mechanism regulating the efflux of the second messenger
outside the cell membrane of viable hGLC cells, according to
previous observation in a wide variety of cell types [34]. The
Table 1. Primer sequences used in real-time PCR experiments.
Gene Oligonucleotide sequences Product length (bp) NCBI Ref. Sequence Protein name
AREG F:GACACCTACTCTGGGAAGCG 121 NM_001657.2 Amphiregulin
R:AAGGCATTTCACTCACAGGG
EREG F:TACTGCAGGTGTGAAGTGGG 139 NM_001432.2 Epiregulin
R:TGGAACCGACGACTGTGATA
NRG1* F:CCCCGATTGAAAGAGATGAA 116 NM_001159999.1 Neuregulin 1
R:TTCCCATTCTTGAACCACTTG
CYP19A1 F:CCCTTCTGCGTCGTGTCAT 86 NM_000103.3 Aromatase
R:GATTTTAACCACGATAGCACTTTCG
RPS7** F: AATCTTTGTTCCCGTTCCTCA 135 NM_001011.3 Ribosomal protein S7
R: CGAGTTGGCTTAGGCAGAA
*Primer chosen to include all NRG1 transcript variants, verified by NCBI BLAST.
**Endogenous control gene.
doi:10.1371/journal.pone.0046682.t001
Figure 1. Dose-response and time-course experiments. a. Dose-
response experiment to r-hLH and r-hCG in COS7/LHCGR in the
presence of 500 mM IBMX. Total cAMP was measured after 3 hours of
incubation and the results of four independent experiments were
plotted (Mean6SEM). b. Time-course experiment performed by
continuous incubation of COS7/LHCGR for different time-points in the
presence of 500 mM IBMX and gonadotropins at ED50 doses (500 pM r-
hLH; 100 pM r-hCG). Intracellular cAMP was measured (n = 3; Mean6
SEM). Asterisk indicates the significant differences of hLH vs hCG (t-test;
p,0.05).
doi:10.1371/journal.pone.0046682.g001
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mechanism of the cyclic hGLC response to constant r-hLH/r-
hCG exposure requires a set of ad hoc experiments and was not
further explored in this setting. However, immunofluorescence
staining revealed membrane localization of the LHCGR in
unstimulated hGLC at each time-point, while the receptor was
visible at the membrane after one hour of stimulation by r-hLH or
r-hCG but prevalently intracellular after 15 and 24 hours,
suggesting possible internalization (Fig. 4). In addition, stimulated
cells tended to assume a typical rounded shape with time, a
phenomenon previously described in granulosa cells exposed to
FSH [35].
Acute effects of hLH and hCG on the ERK1/2 and AKT
pathways in hGLC
We next examined the activation of the ERK1/2- and AKT-
pathways in hGLC. First, we performed dose-response experi-
ments in which phospho-ERK1/2 and phospho-AKT were
detected by Western blotting of protein extracts obtained from
day 6 hGLC stimulated for 15 minutes with different doses of r-
hCG or r-hLH in the pM-nM range. As shown in Fig. 5, the
highest activation of both ERK1/2 and AKT was reached with
100 pM of either gonadotropin. Interestingly, r-hLH appeared
more effective than r-hCG at all doses tested. Differently from
what was observed for cAMP, an equipotent (ED50) dose of the
two gonadotropins on ERK1/2 and AKT activation could not be
determined. Therefore, the maximally stimulating 100 pM dose
was used for both r-hLH and r-hCG in further experiments.
As shown for cAMP dose-response experiments (Fig. S2), a
comparison between recombinant and extractive gonadotropins
was performed in hGL5/LHCGR cells by Western blot, to assess
whether the carbohydrate structure related to recombinant
gonadotropins could affect the phosphorylation rate of ERK1/2
and AKT (Fig. S6). The results obtained were similar, indicating
that recombinant and extractive gonadotropins lead to essentially
the same effects.
The kinetics of ERK1/2 and AKT activation were studied in
time-course experiments using day 6 hGLC in a time range of 5–
60 min. Phospho-ERK1/2 and phospho-AKT signals were
detected by Western blot and semiquantified by image analysis.
Stimulation with 100 pM of r-hLH resulted in a strong, significant
activation of ERK1/2 between 10 and 45 minutes, while 100 pM
of r-hCG induced a much weaker and short-lived stimulation,
reaching significance only at 10 min (Fig. 6). Similar effects were
observed for phospho-AKT. Here again r-hLH (100 pM)
provoked a significant increase in phospho-AKT between 10 to
30 minutes, while the r-hCG (100 pM) stimulation appeared to be
minimal and did not reach statistical significance at any time point
(Fig. 7). The ERK1/2 and AKT activation tended to extinguish
within 60 minutes for both r-hLH and r-hCG stimulations.
These data demonstrate that, in hGLC, r-hLH acutely activates
ERK1/2 and AKT, while r-hCG action is weaker, less sustained
and significant only on the ERK1/2 pathway.
Effects of early blockade of the ERK1/2 or AKT pathway
on hLH- and hCG-mediated gene expression
Given the different effect of r-hLH and r-hCG on acute ERK
and AKT activation, we assessed whether the selective blockade of
these pathways could affect the expression of genes known to be
under hLH and/or hCG control. Day 6 hGLC where exposed to
the specific inhibitors U0126 or LY294002 for one hour and then
stimulated with either r-hLH or r-hCG (100 pM). After 12 hours
gene expression of the EGF-like factors amphiregulin (AREG),
epiregulin (EREG) and neuregulin 1 (NRG1) and of CYP19A1
(aromatase) was quantified by real-time RT-PCR. r-hLH or r-
hCG stimulation resulted in significant stimulation of the
expression of AREG and EREG and inhibition of NRG1 (Fig. 8A
and 8B) and significant stimulation of aromatase (Fig. 8C). In
addition, r-hLH was significantly more potent than r-hCG on
AREG.
Pre-incubation of hGLC with U0126 or LY294002 resulted in
sustained inhibition of ERK1/2 and AKT phosphorylation,
respectively (Fig. S7). The r-hLH- and r-hCG-stimulated expres-
sion of AREG and EREG was not changed by U0126 or LY294002
(data not shown), while inhibition of the ERK or AKT pathway
exerted significant effects on NRG1 expression r-hLH- but not r-
hCG-mediated (Fig. 8B). In fact, both U0126 and LY294002
prevented the decrease of NRG1 expression induced by r-hLH,
indicating that both ERK- and AKT-pathways are involved in the
inhibition of NRG1 expression controlled by r-hLH. Conversely,
neither U0126 nor LY294002 had any effect on r-hCG-inhibited
NRG1 expression, suggesting that the early activation of these
pathways is not involved in r-hCG-mediated action on neuregulin
1, a result consistent with the very weak (or lacking) activation of
these pathways by r-hCG as demonstrated in Fig. 6 and Fig. 7.
As shown in Fig. 8C, the r-hLH- and r-hCG-stimulated gene
expression of CYP19A1 was not affected by LY294002, while
U0126 significantly and specifically increased only r-hLH-stimu-
lated expression. These results demonstrate that the early
activation of the ERK1/2 pathway is involved in hLH- but not
in hCG action on CYP19A1 expression while AKT activation plays
no role.
Discussion
We systematically analyzed whether hLH and hCG are
equivalent in vitro in terms of biopotency, kinetics of response
and molecular effects. It is traditionally believed that hLH and
hCG are biologically equivalent since they act via the same
receptor, for which both molecules are assumed to have the same
binding affinity. hCG has long been the preferred hormone both
in clinical practice and in in vitro experiments because, before the
advent of recombinant gonadotropins, it could be obtained easily
by urinary extraction and owing to its much longer half-life.
However, hLH and not hCG is the physiological hormone in non-
pregnant women and the evolutionary reason for the presence of
hCG in primates has not been clearly established. The vast
majority of our current knowledge about in vitro hLH action on
Leydig and granulosa/theca cells was obtained using hCG. Our
experiments challenge the concept that hLH and hCG have the
same biopotency and bioactivity.
Acute cAMP response
Our results demonstrate that, in vitro, in the presence of a
standardized receptor milieau and at maximal stimulation, hCG is
about 5-times more biopotent than equimolar concentrations of
hLH in terms of cAMP production. Previous in vitro [36] and in vivo
[37–39] studies did not pick up differences between the effects of
hCG and hLH, probably because they were based on gonadotro-
pins not quantified in exact molar terms but in ‘‘units’’ calibrated
against a third preparation, e.g. the standard International
Standard WHO 80/522 [18], or using in vivo bioassay (rat seminal
vesicle weight gain assay). In the latter system, the biopotency ratio
between the two molecules has been evaluated as 1:6 [40] meaning
that, when amounts of hLH and hCG equipotent in vivo are used in
vitro, the molar ratio favours hLH, thereby masking the higher
activity of hCG at the receptor level, which becomes evident when
the two gonadotropins are used in vitro at equimolar concentra-
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Figure 2. Long-term kinetics of intracellular cAMP production and extracellular progesterone and cAMP release in a primary hGLC
sample continuously exposed to r-hLH or r-hCG. Absolute values of intracellular cAMP (bars) and extracellular progesterone (lines) production
by hGLC cultured in the presence IBMX (500 mM) under continuous stimulation by hLH (500 pM) or hCG (100 pM) for up to 36 hours: (a) 0–12 hours,
(b) 13–24 hours, (c) 25–36 hours. cAMP basal level of the unstimulated control cells is also shown for each time-point. d. Measurement of
extracellular cAMP, released in culture medium. One representative of three independent measurement is shown for each graph. Please notice the
different progesterone scale on the Y axis on right side.
doi:10.1371/journal.pone.0046682.g002
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tions. Essentially the same results were observed when hGLC were
used to assess hLH and hCG ED50 (Fig. S3).
The equipotent doses of hLH and hCG were determined by
measuring total cAMP over 3 hours (Fig. 1A) and were confirmed
by progesterone production in hGLC, which reached equal levels
upon hLH or hCG stimulation (Fig. 2). When half-maximal, ED50
concentrations were used in time course-experiments, intracellular
cAMP accumulation resulted about 6-times faster in response to
hLH than hCG (Fig. 1B). Whether the rate of cAMP increase
depends on the levels of receptor occupation, on receptor
dimerization, or on G protein coupling is still unknown. Binding
studies performed formerly with the same cell line [18] showed
that hLH was significantly less potent than hCG in displacing
[125I]hCG, suggesting different binding kinetics. However, this is
not sufficient to establish a difference in receptor affinity for the
two hormones, since the same studies have not been performed in
parallel using [125I]hLH. Binding studies with [125I]hCG and
[125I]hLH would be necessary to assess whether the two hormones
Figure 3. Long-term kinetics of intracellular cAMP production in hGLC continuously exposed to r-hLH or r-hCG. hGLC were cultured in
the presence IBMX (500 mM) under continuous stimulation by r-hLH (500 pM) or r-hCG (100 pM) for up to 36 hours: (a) 0–12 hours, (b) 13–24 hours,
(c) 25–36 hours. Results are means6SEM (n= 3). Asterisks indicate significant differences between hCG and hLH at the given time point (n = 3; t-test;
p,0.05).
doi:10.1371/journal.pone.0046682.g003
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Figure 4. Cellular localization of LHCGR and morphological changes of hGLC under continuous exposure to hLH 500 (pM) by
confocal microscopy. a. Unstimulated cells (control) after 1 hour. b. hLH-treated cells after 1 hour. c. Unstimulated cells after 15 hours. d. LHCGR
sequestration from cell surface in hLH-treated hGLC, after 15 hours. e. Unstimulated cells after 24 hours. f. Cell-rounding in hLH-treated cells after
24 hours. LHCGR is labeled in red (Tritc), the cytoplasmic marker ERK1/2 in green (Fitch) and cell nuclei marker (DAPI) in blue. The merging of the
three images is in the lower right plate of each panel. Images are from one experiment and are representative of three independent experiments with
similar results. White arrows indicated LHCGR; Scale bar: 10 mm. Western blot control for the anti-LHCGR antibody and non-permeabilized cells
control for immunofluorescence staining were also included (Fig. S5).
doi:10.1371/journal.pone.0046682.g004
Figure 5. Dose-response experiment evaluating the maximal phospho-ERK1/2 and phospho-AKT activation in hGLC by Western
blotting. The cells were stimulated for 15 minutes by different r-hLH or r-hCG doses and the phospho-ERK1/2 and phospho-AKT signals were
normalized for total ERK. The image is representative of 3 independent experiments.
doi:10.1371/journal.pone.0046682.g005
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have different affinity/dissociation features. Future experiments
should investigate which residues on the LHCGR, possibly in exon
10, are involved in distinguishing between the two hormones,
whether both hLH and hCG induce receptor dimerization, and
whether the same G proteins are activated by the two hormones.
Since hCG is a primate-specific hormone naturally produced
mainly during pregnancy, it has been speculated that its
occurrence in the evolution of primates might be related to the
complexity of hemochorial placentation [41,42]. At pregnancy
onset the rescue of the corpus luteum is ensured by very low
amounts of hCG produced by the early embryo and pituitary hLH
is not sufficient for this task. Our cAMP in vitro data suggest that, in
an in vivo, ‘‘physiological’’ setting, sustained progesterone produc-
tion could take advantage from the higher activity of hCG,
compared to hLH, at the receptor level, in addition to its longer in
vivo half-life.
Comparison between recombinant and extractive
gonadotropins
The use of recombinant hLH/hCG provides the unique
possibility of comparing effects of both hormones at equimolar
concentrations. Nevertheless, recombinant and extractive gonad-
otropins could differ in extent and type of glycosylation. To assess
whether the possibly different tertiary structure of recombinant
and extractive gonadotropins affect the cell signaling, a compar-
ison between both type of gonadotropins was performed in
different cell models, showing similar results and indicating that
Figure 6. Time-course analysis of the phospho-ERK1/2 activation in hGLC under 100 pM hLH or 100 pM hCG stimulation. a.
Comparison of phospho-ERK1/2 activation in hLH-stimulated vs unstimulated (control) at different time-points, by Western blotting (image is
representative of 4 independent experiments; total ERK as normalizer). b. Comparison of phospho-ERK1/2 activation in hCG-stimulated vs
unstimulated (control) at different time-points, by Western blotting (image is representative of 4 independent experiments; total ERK as normalizer).
c, d. Relative semi-quantification of the optical density representing phospho-ERK1/2 activation (shown in figs. 6A,B) stimulated by (c) hLH or (d)
hCG, compared to unstimulated (Mean6SEM; n = 4; * = significant vs unstimulated; t-test; p,0.05). e. Normalization of the phospho-ERK1/2 signals
measured in hLH-stimulated samples (represented as relative units in Fig. 6C) over each unstimulated (Mean6SEM; n = 4; * = significant vs
unstimulated; two-way analysis of variance; p,0.05). f. Normalization of the phospho-ERK1/2 signals measured in hCG-stimulated samples
(represented as relative units in Fig. 6D) over each unstimulated (Mean6SEM; n= 4; * = significant vs unstimulated; two-way analysis of variance;
p,0.05).
doi:10.1371/journal.pone.0046682.g006
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recombinant and extractive gonadotropins result in essentially
comparable effects (Fig. S2 and Fig. S6).
hLH is secreted as multiple forms by the pituitary, as suggested
by the structural and functional heterogeneity of at least 20
different hLH isoforms with various sialic acid content [43,44],
depending from the purification method used and the source,
pituitary or urinary [45].
hCG is also a heterogenic molecule. It is produced from several
cell types in at least five different forms, (e.g. from cytotrophoblast,
syncytiotrophoblast, pituitary, tumor tissue, etc.) each having the
same amino acid sequence but showing different function
depending on the type and heaviness of glycosylation due to O-
linked and N-linked sugars [46,47]. Recombinant hLH and hCG
are well described [48–50] and they are produced industrially with
the goal of achieving highly consistent molecules by using a
consistent and standardized manufacturing process. However,
there is no extensive physicochemical comparative characteriza-
tion of recombinant and natural, extractive hLH and hCG
molecules, due to the lack of a highly purified reference
preparation and to the different analytical methods used [51].
Using chromatographic procedures the retention time of the
natural and recombinant hLH and hCG molecules are similar,
demonstrating similar hydrophobicity of the alpha and beta
subunits [45]. The only available comparative data between the
Figure 7. Time-course analysis of the phospho-AKT activation in hGLC under 100 pM hLH or 100 pM hCG stimulation. a. Comparison
of phospho-AKT activation in hLH-stimulated vs unstimulated (control) at different time-points, by Western blotting (image is representative of 4
independent experiments; total ERK as normalizer). b. Comparison of phospho-AKT activation in hCG-stimulated vs unstimulated (control) at different
time-points, by Western blotting (image is representative of 4 independent experiments; total ERK as normalizer). c, d. Relative semi-quantification of
the optical density representing phospho-AKT activation (shown in figs. 7A,B) stimulated by (C) hLH or (D) hCG, compared to unstimulated
(Mean6SEM; n = 4; * = significant vs unstimulated; t-test; p,0.05). e. Normalization of the phospho-AKT signals measured in hLH-stimulated samples
(represented as relative units in Fig. 7C) over each unstimulated (Mean6SEM; n = 4; * = significant vs unstimulated; two-way analysis of variance;
p,0.05). f. Normalization of the phospho-AKT signals measured in hCG-stimulated samples (represented as relative units in Fig. 7D) over each
unstimulated (Mean6SEM; n= 4; * = significant vs unstimulated; two-way analysis of variance; p,0.05).
doi:10.1371/journal.pone.0046682.g007
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commercial r-hLH and r-hCG versus the natural forms are
referred to pharmacokinetics and pharmacodynamic studies. Both
recombinant hLH and extractive hLH were eliminated with a
terminal half-life of few hours. The pharmacokinetics of recom-
binant human LH are dose-dependent and similar to those of
extractive human LH [52]. The same holds true for hCG, since r-
hCG and ex-hCG produced bioequivalent pharmacodynamic
responses consistent with the natural physiology of hCG [53].
Chronic cAMP and progesterone response
The experiments with hGLC revealed for the first time that
intracellular cAMP response to constant, chronic stimulation by
hLH or hCG is cyclic, with a period of about 4–5 hours. The
hGLC cell model is naturally expressing the LHCGR and it can
be presumed that the receptor undergoes a kind of ‘‘physiological’’
regulation upon stimulation. Differently, LHCGR gene transcrip-
tion is regulated by the CMV promoter in COS-7/LHCGR and
some discrepancies between hGLC could exist, in terms of
intracellular cAMP regulation. This is the main reason why the
hGLC cell model was used in long-term time-course experiments.
Interestingly, although equipotent doses of hLH and hCG were
used, after the first two-three hours of stimulation cAMP
production was significantly higher in response to hCG than to
hLH at a few time points. The consequence of the intermittent,
intracellular cAMP production was a progressive, massive
secretion of progesterone (a terminal product of steroidogenesis
in granulosa-lutein cells) in the supernatant. Therefore, constant
exposure to hLH or hCG at concentrations close to those
circulating in vivo (as assessed by measuring hLH and hCG by
ELISA in the supernatant) results in the amplification of the
steroidogenic response over time. This is consistent with the
clinical experience that gonadotropin administration does not
need to be pulsatile and with experimental studies in mice [54], in
which continuous and pulsatile infusions of hLH have identical
steroidogenic effects in rats passively immunized against gonad-
otropin-releasing hormone. Therefore, hLH/hCG-responsive
cells, such as hGLC, have developed a mechanism of cyclic
refractoriness of the LHCGR to the chronic, non-pulsatile and
increasing stimulation by hCG occurring in pregnancy, resulting
in a progressive increase of progesterone production. Conversely,
pituitary hLH secretion in non-pregnant women is physiologically
pulsatile and at much lower concentrations compared to hCG
during pregnancy. We speculate that the evolutionary reason why
the two hormones result in these different cAMP production
features could be found in the main role of cAMP plays in
sustaining steroidogenesis as required in pregnancy [55], while LH
has higher activity during folliculogenesis, when the cell cycle
regulators AKT and ERK play a crucial role [56,57]. The
molecular mechanism regulating the fluctuations in intracellular
cAMP response remains to be extensively studied. The presence of
cAMP in the culture medium (Fig. 2D) strongly suggests the
existence of a mechanism regulating the efflux of the second
messenger outside the cell membrane of viable hGLC cells,
according to previous observations in a wide variety of cell types
[34]. In this regard, in primary rat skeletal muscle cultures the loss
of intracellular cAMP from peak levels, induced by activation of
adenylyl cyclase, was followed by an increase of extracellular
cAMP. This effect was not dependent on phosphodiesterases
activation, since it was obtained in the presence of IBMX [58].
Moreover, hGLC are able to downregulate this receptor after in
vivo or in vitro stimulation with gonadotropins [28]. Internalization
of the ligand-receptor complex, downregulation of the mRNA
transcript [31] and phosphorylation of serine or threonine residues
on the receptor molecules [1,28] could be involved. In addition,
receptor dimerization, a feature common to all the G-protein
coupled receptors (GPCRs) [2], might play a role in the activation
of different signalling pathways [59,60] resulting in the cyclic
Figure 8. Evaluation of the gene expression induced in hGLC
by hLH or hCG stimulation after 12 hours, performed by real-
time PCR. Specific ERK1/2- or AKT-pathways inhibitor (U0126 and
LY294002 respectively) were also used where indicated. a. Increase in
the gene expression of the EGF-like factors amphiregulin (AREG) and
epiregulin (EREG) induced by LH or hCG. b. Effects of the hLH or hCG
stimulation and of the ERK1/2- or AKT pathway early inhibition on
neuregulin 1 (NRG1) gene expression. c. Effects of the hLH or hCG
stimulation and of the ERK1/2- or AKT pathway early inhibition on NRG1
gene expression. In each treatments, RPS7 gene expression was used as
normalizer (mean6SEM; n = 4; * = significant vs control; u= significant vs
hLH-stimulated; t-test; p,0.05).
doi:10.1371/journal.pone.0046682.g008
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waving of intracellular cAMP. Finally, post-endocytotic trafficking
of the hormone-receptor complex, which has already been
extensively studied for the FSH receptor (FSHR) [61], the
thyroid-stimulating hormone receptor (TSHR) [61,62] and others
GPCRs [63] could be involved.
Interestingly, hLH and hCG were equipotent in terms of
progesterone production in spite of overall lower cAMP levels
when stimulated by hLH. Progesterone production in preovula-
tory granulosa cells depends on the cAMP/PKA-pathway [64] but
other signalling pathways could be involved [57], e.g. through
molecules of the EGF family such as neuregulin 1 and
amphiregulin [22,65], modulated by ERK1/2 and AKT [66].
Acute activation of the ERK1/2 and AKT pathways and
gene expression
Our data show for the first time in hGLC, that the acute effect
of maximally stimulating doses of hCG on ERK1/2 phosphory-
lation is low when compared to the powerful effect of hLH. These
data were corroborated by the experiments investigating the
consequences of selective inhibition of early ERK1/2 and AKT
activation on the expression of selected hLH- and hCG-dependent
genes. Therefore, while hCG is more potent than LH on the PKA
pathway, hLH is more potent than hCG on the ERK1/2 and
AKT pathways. Interestingly, similar findings were very recently
reported in goat ovarian granulosa cells after prolonged treatment
with supra physiological doses of hLH and hCG [67]. In these
experiments the role of hLH and hCG was investigated in relation
to tumorigenesis and it was shown that hLH promoted growth and
proliferation in caprine ovarian granulosa cells, while hCG was
more active on stimulating cAMP levels and decreased the rate of
proliferation.
The functional role of the cAMP, ERK and AKT signalling
pathways in fertility is actively investigated both in humans [22]
and animal models [57,68,69], revealing that hLH/hCG stimu-
lation of the same receptor results in activation of different,
complex signal transduction pathways and molecules [70–72].
Although recent findings attribute to cAMP the ability to mediate
multiple and opposite effects [73], the in vitro activation of cAMP-
pathway by gonadotropins is traditionally associated to structural
changes, consisting in cell-rounding [19,74], apoptotic events [74–
76] and to prevention of meiosis resumption in the oocyte [77]. In
contrast, gonadotropin-dependent activation of anti-apoptotic
pathways [22,78] and proliferative effects [79] seems to be
mediated by ERK1/2 and AKT, and reduction of ERK1/2
signalling activates apoptotic signals [80]. Granulosa cell death in
vitro can be induced by the specific AKT inhibitor LY294006 and
is completely blocked by hLH co-treatment [78]. Taken together,
these results indicate that hCG and hLH action on the regulation
of cell cycle and apoptosis in granulosa cell might be divergent
and/or dependent on which signal transduction pathway is
activated. This is particularly relevant in determining the cell fate
during folliculogenesis, when the activation of different signal
transduction pathways mediates a delicate balance between pro-
and anti-apoptotic signals [80].
The continuous stimulation of granulosa cells by hLH/hCG
over 12 hours resulted in the increase of AREG, EREG and
CYP19A1 gene expression and in the reduction of NRG1 gene
expression. The EGF-like factors AREG, EREG and NRG1 are well
known target genes of hLH/hCG action [66,81,82]. These
molecules may play a role in the ovulatory process and oocyte
maturation [66,83] exerted via both ERK- and AKT-pathways
activation [22,71]. By using the U0126 or LY294002 inhibitors,
we confirmed the different involvement of the ERK1/2 and AKT
pathways on gene expression in dependence of hLH or hCG. In
accordance with the lower AKT activation by hCG versus hLH,
the inhibition of this pathway by LY294002 did not result in any
relief of the hCG-dependent inhibition of NRG1 expression, while
the inhibitory effect mediated by hLH was prevented by blocking
AKT. Conversely, only the decrease of NRG1 gene expression
induced by hLH was counteracted by inhibition of ERK1/2,
indicating again the relevance of this pathway for hLH- but not for
hCG action. Finally we investigated the expression of CYP19A1
gene, an early-response target of hLH and hCG both in human
[25,84] and in mice [85]. Our data demonstrated a further
increase of CYP19A1 gene expression in U0126 treated cells under
hLH- but not hCG stimulation. In contrast, AKT-pathway
blockade did not affect CYP19A1 gene expression. This suggests
that the ERK-pathway exerts a negative control on aromatase
expression mediated by hLH but not hCG, pinpointing another
relevant difference in the mechanism of action of the two
gonadotropins in hGLC.
Conclusions
The present work provides novel insights in the downstream
signaling of the LHCGR in response to hLH and hCG
stimulation. For the first time we provide evidence that equimolar
concentrations of hLH and hCG result in a higher in vitro activity
of hCG versus hLH in terms of cAMP. Moreover, in hGLC the
LHCGR is able to differentiate the in vitro hLH and hCG action at
the molecular level, affecting the kinetics of cAMP production and
ERK1/2- and AKT-pathway activation. Different signal trans-
duction pathways were also differentially used to reach an equal
transcriptional level of target genes by both gonadotropins, but
how LHCGR modulates the activation of different signalling
pathways depending on the ligand remains to be clarified. Our
study was so far limited at assessing the acute effects of hLH and
hCG and future experiments should be dedicated to the events
following the early activation of the various pathways and their
interaction, resulting in the final, full biological effects. Finally,
while the in vivo effects of the differential activation of the various
pathways remain to be studied in detail, the nonequivalence of
hLH and hCG deserves consideration in the development of
future therapeutic strategies [86].
Supporting Information
Figure S1 Recovery of hGLC response to hLH and hCG,
over 0–6 days from in vivo pick-up. Total cAMP measured
on the (a) third and (b) sixth day of culture are shown.
(TIF)
Figure S2 Comparison between recombinant and ex-
tractive gonadotropins effects on total cAMP production.
a. Dose-response experiment with r-hLH and r-hCG versus ex-
hLH and ex-hCG in COS7/LHCGR, in the presence of 500 mM
IBMX. Total cAMP was measured after 3 hours. One represen-
tative experiment is shown. b. The experiment shown in panel
‘‘a’’ has been repeated using hGL5/LHCGR, in the presence of
500 mM IBMX. Total cAMP was measured after 3 hours. One
representative experiment is shown.
(TIF)
Figure S3 Dose-response and time-course experiments
in hGLC. a. Dose-response experiment with r-hLH and r-hCG
in hGLC in the presence of 500 mM IBMX. Total cAMP was
measured after 3 hours. One of three independent experiments is
shown. b. Time-course experiment performed by continuous
incubation of hGLC for different time-points in the presence of
500 mM IBMX and gonadotropins at ED50 doses (500 pM r-hLH;
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100 pM r-hCG). Intracellular cAMP was measured. One of three
independent experiments is shown in absolute levels.
(TIF)
Figure S4 Intracellular cAMP production over 6 hours in
hGLC stimulated by hLH (500 pM) or hCG (100 pM). Each
value was normalized vs unstimulated. One representative
experiment of two is shown.
(TIF)
Figure S5 Control samples of immunofluorescence
analysis. Non-permeabilized cells control of LHCGR sequestra-
tion from cell surface in hLH-treated hGLC, after 15 hours. a.
Unstimulated cells. b. hLH-treated hGLC. LHCGR is labeled in
red (Tritc), the cytoplasmic marker ERK1/2 in green (Fitch) and
cell nuclei marker (DAPI) in blue. The merging of the three images
is in the lower right plate of each panel. Images are from one
experiment and are representative of three independent experi-
ments with similar results. c. Western blot control for anti-
LHCGR antibody performed on 1) COS7/LHCGR cell lysates; 2)
hGL5/LHCGR cell lysates; 3) Untrasfected hGL5 cell lysates
(negative control); 4) and 5) hGLC cell lysates from two different
donors.
(TIF)
Figure S6 Comparison between recombinant and ex-
tractive gonadotropin effect on ERK1/2 and AKT
phosphorylation. Dose-response experiment evaluating the
maximal phospho-ERK1/2 and phospho-AKT activation in
hGL5/LHCGR by Western blotting. The cells were stimulated
for 15 minutes by different recombinant or extractive hLH or
hCG doses and the phospho-ERK1/2 and phospho-AKT signals
were normalized for total ERK. One representative experiment is
shown.
(TIF)
Figure S7 Western blot analysis of phospho ERK1/2 (a) and
phospho AKT (b) and efficacy of the relative inhibitors U0126 and
LY294002 in hGLC stimulated for 15 with hLH or hCG.
(TIF)
Methods S1 Supplementary Methods
(DOCX)
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